COMMUNIQUÉS West-GlobeNewswire

Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

05/11/2024 - 15:00

Poster presentation highlights long-lived functional persistence, anti-tumor activity, and maintenance of stem central memory phenotype of OPB-101 cell product SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Outpace Bio , a [...]

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

05/11/2024 - 15:00

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer [...]

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

05/11/2024 - 15:00

– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR [...]

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting

05/11/2024 - 15:00

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM Company will also present safety and tolerability data from Phase 1/2 study of ISB 1442 in r/r MM [...]

Auron to Present New Preclinical Data for AUTX-703 at 2024 ASH Meeting

05/11/2024 - 15:00

NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics , a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, [...]

Pacific Eye Associates Selects Nextech

05/11/2024 - 15:00

Multi-Specialty Ophthalmology Practice to Standardize on Ophthalmic Platform TAMPA, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nextech, market leader of comprehensive technology solutions for specialty physician practices [...]

Revolution Medicines to Participate in Upcoming Investor Conferences

05/11/2024 - 15:00

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. [...]

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

05/11/2024 - 15:00

Abstract selected as poster presentation during the Society for Immunotherapy of Cancer (SITC) Annual Meeting shows potent antitumor activity of CAN-3110 in preclinical models of melanoma CAN-3110's activity is designed [...]

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

05/11/2024 - 15:01

-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treatment centers ( [...]

Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer

05/11/2024 - 15:01

Lynch Syndrome (LS) is a common hereditary condition (affecting one in 300) conferring a high risk of developing colorectal, gastric, endometrial and other cancers NOUS-209 monotherapy is well tolerated and generates [...]

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

05/11/2024 - 15:01

Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of [...]

Umoja Biopharma Announces Oral and Poster Presentations at the 66th American Society of Hematology Annual Meeting

05/11/2024 - 15:05

SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies [...]

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

05/11/2024 - 15:05

– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% observed at CNTY-101 [...]

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

05/11/2024 - 15:05

– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in [...]

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

05/11/2024 - 15:09

– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7 th – – Ziftomenib combined with ven/aza in R/R NPM1-m or KMT2A-r AML patients [...]

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

05/11/2024 - 15:10

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma MRD data to be [...]

Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024

05/11/2024 - 15:15

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66 th American Society of Hematology (ASH) Annual Meeting and [...]

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

05/11/2024 - 15:15

All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with AML, ALL, or MDS [...]

Healthcare Integrated Technologies, Inc. Appoints Caleb Dixon as Chief Customer Officer

05/11/2024 - 15:16

Knoxville, Tennessee, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. (HiTC), a leader in AI-driven healthcare solutions, is pleased to announce the appointment of Caleb Dixon as Chief [...]